WO2023053032 - AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
National phase entry:
Publication Number
WO/2023/053032
Publication Date
06.04.2023
International Application No.
PCT/IB2022/059240
International Filing Date
28.09.2022
Title **
[English]
AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
[French]
PROCÉDÉ AMÉLIORÉ DE PURIFICATION DE PROTÉINE DE FUSION
Applicants **
KASHIV BIOSCIENCES, LLC
20, New England Avenue
Piscataway, New Jersey 08854, US
Inventors
NARAYAN, Om
802, Anvayaa, Makarba Road, Vejalpur, Ahmedabad, Gujarat
Ahmedabad 380051, IN
THAKKAR, Mayankkumar
C501, Setu Vertica, B/H Vodaphone Tower, Gota, Ahmedabad, Gujarat
Ahmedabad 382481, IN
KUMAR, Anuj
6/2, New Kishore Ganj, Ranchi, Jharkhand
Ranchi 834001, IN
Priority Data
202121043969
28.09.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1103 | |
| EPO | Filing, Examination | 6447 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2880 |
Total: 11594 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the fusion protein, substantially free of misfolded species, charge variants and aggregates. A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity.[French]
La présente invention concerne un procédé de purification d'une protéine de fusion 4-immunoglobuline associée aux lymphocytes T cytotoxiques (CTLA4-Ig) pharmacologiquement active par l'utilisation de trois étapes de chromatographie en colonne qui fournit une forme purifiée de la protéine de fusion, sensiblement exempte d'espèces mal repliées, de variants de charge et d'agrégats. L'invention concerne également une méthode de purification d'une protéine de fusion à partir d'un mélange protéique comprenant une protéine de fusion et une impureté à poids moléculaire élevé (HMW).